Alnylam Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Alnylam Pharmaceuticals has been growing earnings at an average annual rate of 12.1%, while the Biotechs industry saw earnings growing at 13.2% annually. Revenues have been growing at an average rate of 40.7% per year.
Key information
12.1%
Earnings growth rate
14.6%
EPS growth rate
| Biotechs Industry Growth | 14.8% |
| Revenue growth rate | 40.7% |
| Return on equity | -1,027.0% |
| Net Margin | -15.9% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Alnylam Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 2,095 | -332 | 878 | 1,098 |
| 30 Jun 24 | 2,344 | -73 | 856 | 1,080 |
| 31 Mar 24 | 2,003 | -332 | 823 | 1,035 |
| 31 Dec 23 | 1,828 | -440 | 796 | 1,004 |
| 30 Sep 23 | 1,724 | -510 | 808 | 994 |
| 30 Jun 23 | 1,237 | -1,064 | 845 | 987 |
| 31 Mar 23 | 1,143 | -1,065 | 800 | 944 |
| 31 Dec 22 | 1,037 | -1,131 | 771 | 883 |
| 30 Sep 22 | 961 | -1,182 | 747 | 850 |
| 30 Jun 22 | 884 | -981 | 653 | 799 |
| 31 Mar 22 | 880 | -893 | 628 | 776 |
| 31 Dec 21 | 844 | -853 | 621 | 792 |
| 30 Sep 21 | 749 | -838 | 619 | 713 |
| 30 Jun 21 | 688 | -887 | 662 | 662 |
| 31 Mar 21 | 571 | -876 | 663 | 617 |
| 31 Dec 20 | 493 | -858 | 588 | 655 |
| 30 Sep 20 | 401 | -891 | 646 | 620 |
| 30 Jun 20 | 345 | -846 | 594 | 624 |
| 31 Mar 20 | 286 | -886 | 574 | 637 |
| 31 Dec 19 | 220 | -886 | 534 | 600 |
| 30 Sep 19 | 169 | -821 | 482 | 534 |
| 30 Jun 19 | 101 | -858 | 477 | 515 |
| 31 Mar 19 | 86 | -802 | 446 | 491 |
| 31 Dec 18 | 75 | -761 | 425 | 463 |
| 30 Sep 18 | 92 | -692 | 379 | 454 |
| 30 Jun 18 | 107 | -570 | 306 | 414 |
| 31 Mar 18 | 93 | -525 | 264 | 370 |
| 31 Dec 17 | 90 | -491 | 230 | 360 |
| 30 Sep 17 | 69 | -462 | 191 | 346 |
| 30 Jun 17 | 66 | -443 | 166 | 349 |
| 31 Mar 17 | 59 | -414 | 137 | 342 |
| 31 Dec 16 | 47 | -410 | 119 | 352 |
| 30 Sep 16 | 37 | -388 | 106 | 333 |
| 30 Jun 16 | 30 | -361 | 98 | 305 |
| 31 Mar 16 | 30 | -342 | 93 | 291 |
| 31 Dec 15 | 41 | -290 | 82 | 255 |
| 30 Sep 15 | 58 | -221 | 78 | 229 |
| 30 Jun 15 | 62 | -188 | 71 | 208 |
| 31 Mar 15 | 61 | -160 | 67 | 186 |
| 31 Dec 14 | 51 | -360 | 63 | 172 |
| 30 Sep 14 | 37 | -371 | 56 | 150 |
| 30 Jun 14 | 35 | -357 | 52 | 139 |
| 31 Mar 14 | 37 | -331 | 45 | 119 |
| 31 Dec 13 | 47 | -89 | 41 | 99 |
Quality Earnings: A1LN34 is currently unprofitable.
Growing Profit Margin: A1LN34 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A1LN34 is unprofitable, but has reduced losses over the past 5 years at a rate of 12.1% per year.
Accelerating Growth: Unable to compare A1LN34's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A1LN34 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4%).
Return on Equity
High ROE: A1LN34 has a negative Return on Equity (-1026.96%), as it is currently unprofitable.